Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

[1]  Hiroshi Ito,et al.  Postprandial hyperlipidemia as a potential residual risk factor. , 2016, Journal of cardiology.

[2]  E. Nozaki,et al.  Different postprandial lipid metabolism and insulin resistance between non-diabetic patients with and without coronary artery disease. , 2015, Journal of cardiology.

[3]  J. Jankowski,et al.  Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities , 2015, Front. Immunol..

[4]  S. Yamashita,et al.  Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria. , 2014, Journal of atherosclerosis and thrombosis.

[5]  Mahboob Rahman,et al.  Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[6]  M. Landray,et al.  Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP) , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  S. Fukumoto,et al.  Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus. , 2014, Journal of atherosclerosis and thrombosis.

[8]  K. Homma,et al.  Triglyceride‐rich lipoproteins in chronic kidney disease patients undergoing maintenance haemodialysis treatment , 2012, International journal of clinical practice.

[9]  J. Obata,et al.  Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. , 2011, Atherosclerosis.

[10]  G. Riccardi,et al.  Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. , 2011, Atherosclerosis.

[11]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[12]  Mark Woodward,et al.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[13]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  J. Tomassini,et al.  Ezetimibe: cholesterol lowering and beyond , 2008, Expert review of cardiovascular therapy.

[15]  F. Kronenberg,et al.  Lipoprotein metabolism and lipid management in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[16]  Kdoqi.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  Kingston H. Tseng,et al.  Standards of Medical Care in Diabetes–2006 , 2006, Diabetes Care.

[18]  M. Zwahlen,et al.  Apolipoprotein B as a long‐term predictor of mortality in type 1 diabetes mellitus: a 15‐year follow up , 2006, Journal of internal medicine.

[19]  V. Chair,et al.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the , 2006, Stroke.

[20]  Nader Rifai,et al.  Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. , 2004, Diabetes care.

[21]  K. Kugiyama,et al.  Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. , 2004, Journal of the American College of Cardiology.

[22]  R. Krauss.  Lipids and lipoproteins in patients with type 2 diabetes. , 2004, Diabetes care.

[23]  R. D'Agostino,et al.  The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. , 2004, Diabetes care.

[24]  S. Proctor,et al.  Intimal Retention of Cholesterol Derived From Apolipoprotein B100– and Apolipoprotein B48–Containing Lipoproteins in Carotid Arteries of Watanabe Heritable Hyperlipidemic Rabbits , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[25]  O. Samuelsson,et al.  Dialysis modalities and dyslipidemia. , 2003, Kidney international. Supplement.

[26]  W. März,et al.  Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations , 2000, Circulation.

[28]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .

[29]  K. Kugiyama,et al.  Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. , 2000, Circulation.

[30]  K. Kugiyama,et al.  Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. , 1998, Circulation.

[31]  R. Krauss,et al.  Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. , 1997, Circulation.

[32]  K. Nakajima,et al.  Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[33]  A. Tybjærg‐Hansen,et al.  IDL, VLDL, chylomicrons and atherosclerosis , 1992, European Journal of Epidemiology.

[34]  P. Nestel,et al.  Lipoprotein predictors of the severity of coronary artery disease in men and women. , 1985, Circulation.

[35]  J. Obata,et al.  High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. , 2009, Atherosclerosis.

[36]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[37]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[38]  ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[39]  N. Levin,et al.  High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.